Amarin Corp Plcuk (AMRN) Total Liabilities (2010 - 2026)
Amarin Corp Plcuk (AMRN) posted quarterly Total Liabilities of $196.4 million for Q1 2026, up 7.89% YoY from $182.0 million in Q1 2025, and down 7.16% sequentially from $211.5 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Total Liabilities (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk has disclosed Total Liabilities across 17 years of filings, most recently posting $196.4 million for Q1 2026.
- In Q1 2026, Total Liabilities rose 7.89% year-over-year to $196.4 million; the TTM figure through Mar 2026 stood at $196.4 million (up 7.89% YoY), while the FY2025 annual figure was $211.5 million, up 6.19% from the prior year.
- Total Liabilities slipped to $196.4 million in Q1 2026, from $211.5 million in the prior quarter.
- Over the last five years, Total Liabilities for AMRN reached as high as $393.2 million in Q2 2022 and fell as low as $182.0 million in Q1 2025.
- The 5-year median for Total Liabilities is $248.0 million (2024), against an average of $257.4 million.
- Annual changes were most pronounced in 2024 — Total Liabilities declined 28.76% — and 2026, when it grew 7.89%.
- A 5-year view of Total Liabilities shows it stood at $290.8 million in 2022, then decreased by 3.87% to $279.6 million in 2023, then decreased by 28.76% to $199.2 million in 2024, then grew by 6.19% to $211.5 million in 2025, then declined by 7.16% to $196.4 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $196.4 million, $211.5 million, and $200.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 85.38 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 119.71 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 143.12 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -66.63 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 82.81 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 83.31 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 32.76 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 117.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn | 196.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 196.35 Mn |
| Dec 31, 2025 | 211.49 Mn |
| Sep 30, 2025 | 200.92 Mn |
| Jun 30, 2025 | 205.20 Mn |
| Mar 31, 2025 | 181.99 Mn |
| Dec 31, 2024 | 199.17 Mn |
| Sep 30, 2024 | 219.24 Mn |
| Jun 30, 2024 | 247.98 Mn |
| Mar 31, 2024 | 244.08 Mn |
| Dec 31, 2023 | 279.59 Mn |
| Sep 30, 2023 | 285.88 Mn |
| Jun 30, 2023 | 290.89 Mn |
| Mar 31, 2023 | 275.40 Mn |
| Dec 31, 2022 | 290.85 Mn |
| Sep 30, 2022 | 320.48 Mn |
| Jun 30, 2022 | 393.19 Mn |
| Mar 31, 2022 | 332.60 Mn |
| Dec 31, 2021 | 400.97 Mn |
| Sep 30, 2021 | 393.31 Mn |
| Jun 30, 2021 | 399.67 Mn |